See more : Regeneron Pharmaceuticals, Inc. (0R2M.L) Income Statement Analysis – Financial Results
Complete financial analysis of Vivoryon Therapeutics N.V. (0R3M.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vivoryon Therapeutics N.V., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Plaza Wires Limited (PLAZACABLE.BO) Income Statement Analysis – Financial Results
- ioneer Ltd (INR.AX) Income Statement Analysis – Financial Results
- Suga International Holdings Limited (0912.HK) Income Statement Analysis – Financial Results
- Yunnan Baiyao Group Co.,Ltd (000538.SZ) Income Statement Analysis – Financial Results
- PT Mitra Pemuda Tbk (MTRA.JK) Income Statement Analysis – Financial Results
Vivoryon Therapeutics N.V. (0R3M.L)
About Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -3.62M | 0.00 | 10.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.00K | 21.00K |
| Cost of Revenue | -525.00K | 161.00K | 1.73M | 146.00K | 88.00K | 23.00K | 106.00K | 97.00K | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.10M | -161.00K | 9.03M | -146.00K | -88.00K | -23.00K | -106.00K | -97.00K | -56.00K | 0.00 | 0.00 | 6.00K | 21.00K |
| Gross Profit Ratio | 85.50% | 0.00% | 83.89% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 17.64M | 20.22M | 17.45M | 13.21M | 4.75M | 4.84M | 7.45M | 10.95M | 10.16M | 8.01M | 8.00M | 9.26M | 13.23M |
| General & Administrative | 3.27M | 8.91M | 4.55K | 2.81M | 3.06M | 2.89M | 2.51M | 2.91M | 3.28M | 3.32M | 2.39M | 2.34M | 3.08M |
| Selling & Marketing | 3.00K | 8.74M | 4.38M | 2.66M | 2.93M | 2.87M | 2.40M | 2.81M | 3.22M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.27M | 8.75M | 4.38M | 2.66M | 2.94M | 2.87M | 2.41M | 2.81M | 3.22M | 3.32M | 2.39M | 2.34M | 3.08M |
| Other Expenses | 4.83M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -747.00K | -1.03M | -2.02M |
| Operating Expenses | 25.74M | 28.97M | 21.84M | 15.87M | 7.69M | 7.70M | 9.86M | 13.76M | 13.38M | 11.27M | 9.65M | 10.56M | 14.29M |
| Cost & Expenses | 25.22M | 29.13M | 23.57M | 16.02M | 7.77M | 7.73M | 9.97M | 13.86M | 13.44M | 11.27M | 9.65M | 10.56M | 14.29M |
| Interest Income | 478.00K | 42.00K | 21.00K | 26.00K | 31.00 | 39.00 | 850.00 | 114.00 | 112.00 | 170.00 | 9.00K | 22.00K | 42.00K |
| Interest Expense | 56.00K | 24.00K | 24.00K | 23.00K | 108.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 115.00K | 340.00K | 71.00K |
| Depreciation & Amortization | 167.00K | 161.00K | 165.00K | 146.00K | 88.00K | 23.00K | 106.00K | 97.00K | 56.00K | 94.00K | 314.00K | 352.00K | 413.00K |
| EBITDA | -28.35M | -28.17M | -12.03M | -16.34M | -7.63M | -7.68M | -9.86M | -13.68M | -13.34M | -11.17M | -9.34M | -10.18M | -13.78M |
| EBITDA Ratio | 783.23% | 0.00% | -117.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -169,666.67% | -65,604.76% |
| Operating Income | -28.84M | -29.13M | -12.81M | -16.02M | -7.77M | -7.73M | -9.97M | -13.86M | -13.44M | -11.27M | -9.65M | -10.56M | -14.27M |
| Operating Income Ratio | 796.60% | 0.00% | -118.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -175,966.67% | -67,947.62% |
| Total Other Income/Expenses | 261.00K | 777.00K | 575.00K | -493.00K | -49.00K | -10.00K | 854.00K | -31.00K | -68.00K | -170.00K | -106.00K | -314.00K | 8.00K |
| Income Before Tax | -28.58M | -28.36M | -12.22M | -16.51M | -7.82M | -7.74M | -9.11M | -13.89M | -13.51M | -11.44M | -9.76M | -10.87M | -14.26M |
| Income Before Tax Ratio | 789.39% | 0.00% | -113.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -181,200.00% | -67,909.52% |
| Income Tax Expense | -234.00K | -199.00K | 432.00K | 0.00 | 0.00 | -138.14K | -1.10M | 0.00 | 0.00 | 0.00 | 172.00K | 656.00K | -6.00K |
| Net Income | -28.34M | -28.16M | -12.66M | -16.51M | -7.82M | -7.74M | -8.01M | -13.89M | -13.51M | -11.44M | -9.93M | -18.72M | -16.31M |
| Net Income Ratio | 782.93% | 0.00% | -117.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -312,000.00% | -77,652.38% |
| EPS | -1.12 | -1.28 | -0.63 | -0.83 | -0.62 | -0.92 | -0.96 | -1.79 | -1.93 | -2.35 | -1.35 | -2.55 | -2.22 |
| EPS Diluted | -1.12 | -1.28 | -0.63 | -0.83 | -0.62 | -0.92 | -0.96 | -1.79 | -1.93 | -2.35 | -1.35 | -2.55 | -2.22 |
| Weighted Avg Shares Out | 25.24M | 22.02M | 20.00M | 19.98M | 12.55M | 8.37M | 8.35M | 7.77M | 7.01M | 4.86M | 7.34M | 7.34M | 7.34M |
| Weighted Avg Shares Out (Dil) | 25.24M | 22.02M | 20.00M | 19.98M | 12.55M | 8.37M | 8.35M | 7.77M | 7.01M | 4.86M | 7.34M | 7.34M | 7.34M |
Source: https://incomestatements.info
Category: Stock Reports